Literature DB >> 19008647

A novel chalcone polyphenol inhibits the deacetylase activity of SIRT1 and cell growth in HEK293T cells.

Tomoaki Kahyo1, Shuji Ichikawa, Takahiro Hatanaka, Maki K Yamada, Mitsutoshi Setou.   

Abstract

SIRT1 is one of seven mammalian orthologs of yeast silent information regulator 2 (Sir2), and it functions as a nicotinamide adenine dinucleotide (NAD)-dependent deacetylase. Recently, resveratrol and its analogues, which are polyphenols, have been reported to activate the deacetylase activity of SIRT1 in an in vitro assay and to expand the life-span of several species through Sir2 and the orthologs. To find activators or inhibitors to SIRT1, we examined thirty-six polyphenols, including stilbenes, chalcones, flavanones, and flavonols, with the SIRT1 deacetylase activity assay using the acetylated peptide of p53 as a substrate. The results showed that 3,2',3',4'-tetrahydroxychalcone, a newly synthesized compound, inhibited the SIRT1-mediated deacetylation of a p53 acetylated peptide and recombinant protein in vitro. In addition, this agent induced the hyperacetylation of endogenous p53, increased the endogenous p21CIP1/WAF1 in intact cells, and suppressed the cell growth. These results indicated that 3,2',3',4'-tetrahydroxychalcone had a stronger inhibitory effect on the SIRT1-pathway than sirtinol, a known SIRT1-inhibitor. Our results mean that 3,2',3',4'-tetrahydroxychalcone is a novel inhibitor of SIRT1 and produces physiological effects on organisms probably through inhibiting the deacetylation by SIRT1.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19008647     DOI: 10.1254/jphs.08203fp

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  15 in total

Review 1.  Sirtuin activators and inhibitors: Promises, achievements, and challenges.

Authors:  Han Dai; David A Sinclair; James L Ellis; Clemens Steegborn
Journal:  Pharmacol Ther       Date:  2018-03-22       Impact factor: 12.310

Review 2.  Sirtuin modulators.

Authors:  Sumit S Mahajan; Vid Leko; Julian A Simon; Antonio Bedalov
Journal:  Handb Exp Pharmacol       Date:  2011

Review 3.  p53-based cancer therapy.

Authors:  David P Lane; Chit Fang Cheok; Sonia Lain
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-05-12       Impact factor: 10.005

Review 4.  Molecular targeted approaches to cancer therapy and prevention using chalcones.

Authors:  Danielle D Jandial; Christopher A Blair; Saiyang Zhang; Lauren S Krill; Yan-Bing Zhang; Xiaolin Zi
Journal:  Curr Cancer Drug Targets       Date:  2014       Impact factor: 3.428

5.  Leptin attenuates BACE1 expression and amyloid-β genesis via the activation of SIRT1 signaling pathway.

Authors:  Gurdeep Marwarha; Shaneabbas Raza; Craig Meiers; Othman Ghribi
Journal:  Biochim Biophys Acta       Date:  2014-05-27

6.  Identification and characterization of novel sirtuin inhibitor scaffolds.

Authors:  Brandi D Sanders; Brittany Jackson; Michael Brent; Alexander M Taylor; Weiwei Dang; Shelley L Berger; Stuart L Schreiber; Konrad Howitz; Ronen Marmorstein
Journal:  Bioorg Med Chem       Date:  2009-08-03       Impact factor: 3.641

Review 7.  Rejuvenating sirtuins: the rise of a new family of cancer drug targets.

Authors:  Santina Bruzzone; Marco Daniele Parenti; Alessia Grozio; Alberto Ballestrero; Inga Bauer; Alberto Del Rio; Alessio Nencioni
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

8.  Piceatannol and its metabolite, isorhapontigenin, induce SIRT1 expression in THP-1 human monocytic cell line.

Authors:  Shinpei Kawakami; Yosuke Kinoshita; Hiroko Maruki-Uchida; Koji Yanae; Masahiko Sai; Tatsuhiko Ito
Journal:  Nutrients       Date:  2014-10-30       Impact factor: 5.717

9.  Piceatannol exhibits anti-inflammatory effects on macrophages interacting with adipocytes.

Authors:  Takayuki Yamamoto; Yongjia Li; Yuki Hanafusa; Yu-Sheng Yeh; Hiroko Maruki-Uchida; Shinpei Kawakami; Masahiko Sai; Tsuyoshi Goto; Tatsuhiko Ito; Teruo Kawada
Journal:  Food Sci Nutr       Date:  2016-05-16       Impact factor: 2.863

10.  Diverse Molecular Targets for Chalcones with Varied Bioactivities.

Authors:  Bo Zhou; Chengguo Xing
Journal:  Med Chem (Los Angeles)       Date:  2015-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.